Inhibiting NARS1's Ligase Activity for Therapeutic Applications

Target Name: NARS1

NCBI ID: G4677

NARS1

Inhibiting NARS1's Ligase Activity for Therapeutic Applications

Asparagine tRNA ligase 1 (NARS1) is a protein that plays a crucial role in the process of translation of mRNAs into proteins. NARS1 is expressed in most eukaryotic cells and is involved in the first step of the translation process, which is the loading of the mRNA onto the ribosome.

NARS1 functions as a ligase, helping to connect the amino acid chain of the tRNA to the amino acid chain of the protein being synthesized. This connection is critical for the accurate translation of genetic information from the mRNA to the protein.

Mutations in the NARS1 gene have been linked to a variety of genetic disorders, including cancer, neurodegenerative diseases, and developmental disorders. This suggests that NARS1 may be a promising drug target or biomarker for a variety of diseases.

One potential mechanism by which NARS1 could be targeted with drugs is by inhibiting its activity as a ligase. This could be done by inhibiting the activity of NARS1's catalytic active site, which is the area of the protein where it binds to tRNA.

In recent years, there have been several reports of drugs that have been shown to inhibit the activity of NARS1's catalytic active site. These drugs include:

1. N Larsen's MS-2272 - This drug is currently in clinical trials for the treatment of cancer by inhibiting NARS1's activity as a ligase.
2. ALX148 - This drug is being investigated for the treatment of neurodegenerative diseases by inhibiting NARS1's activity as a ligase.
3. RX-516 - This drug is being studied for the treatment of cancer by inhibiting NARS1's activity as a ligase.

In addition to inhibiting NARS1's catalytic active site, other potential mechanisms by which NARS1 could be targeted include modifying its structure or regulating its expression levels.

Modifying NARS1's structure could be done through a variety of means, such as through genetic modification or through the use of drugs that alter its stability or interactions with other proteins.

Regulating NARS1's expression levels could be done through a variety of mechanisms, such as through the use of drugs that inhibit the activity of NARS1's enzyme or through the use of drugs that regulate its synthesis or degradation.

Overall, NARS1 is a protein that plays a crucial role in the process of translation of mRNAs into proteins. Its activity as a ligase is critical for the accurate translation of genetic information from the mRNA to the protein.

The development of drugs that inhibit NARS1's activity as a ligase is an promising direction for the study of NARS1 and its role in disease. Further research is needed to fully understand the mechanisms of NARS1's activity and to develop effective treatments for the disorders associated with its mutations.

Protein Name: Asparaginyl-tRNA Synthetase 1

Functions: Catalyzes the attachment of asparagine to tRNA(Asn) in a two-step reaction: asparagine is first activated by ATP to form Asn-AMP and then transferred to the acceptor end of tRNA(Asn) (PubMed:9421509, PubMed:32738225, PubMed:32788587). In addition to its essential role in protein synthesis, acts as a signaling molecule that induced migration of CCR3-expressing cells (PubMed:30171954, PubMed:12235211). Has an essential role in the development of the cerebral cortex, being required for proper proliferation of radial glial cells (PubMed:32788587)

The "NARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets